Dear customer, upon your request Yescarta Company were found the following resources. Our team makes effort to make you happy with the search on our site ninan.org

Kite Pharma

Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development. For the past three decades, members of our team have been at the forefront of ……

Yescarta - And More

Yescarta was developed by biotech company Kite Pharma, which was acquired by Gilead Sciences in an $11.9 billion deal in August 2017. Based on the ZUMA-1 trial, Kite submitted to the FDA a biologics license application for Yescarta in March 2017 for the treatment of Non-Hodgkin lymphoma.…

New Cancer Treatment – Learn about CAR T Immunotherapy

YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from ...…

The FDA Approves a Second CAR-T Therapy, Cheaper than ...

Gilead's CAR-T cell therapy Yescarta has been approved by the FDA, making it the first competitor for Novartis' CAR-T Kymriah. Yescarta (axicabtagene ciloleucel, or axi-cel for short) has become the second CAR-T therapy to be approved in the US. The FDA has authorized its use to treat aggressive B-cell non-Hodgkin lymphoma in patients for whom at least two other types of treatments for their ...…

Yescarta (axicabtagene ciloleucel

The company that markets Yescarta must ensure that hospitals where Yescarta is given have appropriate expertise, facilities and training. Tocilizumab must be available in case of cytokine release syndrome. The company must provide educational materials for healthcare professionals and patients…